Idera Pharmaceuticals Inc.

Since joining the Company in 1990, Dr. Agrawal has served in various capacities including Vice President of Discovery, Senior Vice President of Discovery, and Acting Chief Executive Officer. He was appointed Chief Scientific Officer in January 1993, President in February 2000, and Chief Executive Officer in August 2004. Dr. Agrawal has led the Company's transition into the discovery and development of targeted immune therapy based on Toll-like receptors. Dr. Agrawal received his D. Phil. in Chemistry in 1980 and carried out his post-doctoral research at the Medical Research Council's Laboratory of Molecular Biology in Cambridge, U.K. While working at Worcester Foundation of Experimental Biology, he carried out work in antisense technology with Paul Zamecnik, MD, and based on this technology, the Company was founded. Dr. Agrawal has published over 275 research papers/reviews and has edited two volumes on oligonucleotide chemistry and one on antisense therapeutics. He has also authored over 300 patents, issued or pending worldwide. He is a member of the editorial board of Oligonucleotides, Trends in Molecular Medicine, IDrugs, and Human Vaccines.

Mr. Arcudi joined the Company in 2007 as Chief Financial Officer. From 2003-2007, Mr. Arcudi served as Vice President of Finance and Administration and Treasurer for Peptimmune, Inc. and was responsible for all financial business and operations. Prior to joining Peptimmune, Mr. Arcudi was Senior Director of Finance and Administration at Genzyme Molecular Oncology Corporation from 2000-2003 and Director of Finance Business Planning and Operations International at Genzyme Corporation from 1998-2000. Prior to joining Genzyme, he held finance positions with increasing levels of responsibility at Cognex Corporation, Millipore Corporation and General Motors Corporation. Mr. Arcudi received a Master of Business Administration from Bryant College and a Bachelor of Science Degree in accounting and information systems from the University of Southern New Hampshire.

Dr. Bexon joined the Company in 2007. From 2001 to 2006, Dr. Bexon worked for Hoffmann La Roche's Pharma Division, where she served initially as International Medical Leader for the Oncology Business organization and subsequently as Clinical Science Leader for Pharma Development Medical Oncology. Dr. Bexon also served as Medical Director in the oncology business unit of Sanofi-Synthelabo's French affiliate (now Sanofi-Aventis). In addition, Dr. Bexon worked for the European Organization for Research and Treatment of Cancer (subsequently NDDO Oncology) in the Netherlands and Parexel International in France. Dr. Bexon brings a comprehensive knowledge of clinical drug development to the Company, particularly in oncology. Dr. Bexon received her MB ChB (MD equivalent) from Bristol University Medical School in the UK in 1994 and her full General Medical Council registration to practice medicine the following year. She completed internships in internal medicine and general surgery at Newcastle's Freeman and North Tyneside General Hospitals in the UK and her oncology residency under Professor Jean-Pierre Armand at the Institut Gustave Roussy in Villejuif, France.

Dr. Kandimalla joined the Company as a Senior Research Scientist in 1992 with extensive experience in chemistry and biochemistry of nucleic acids. From 1993-1999, Dr. Kandimalla served as Senior Scientist, and from 1999-2004 he was Director of Functional Genomics. In 2004, he served as Senior Director of Research. Dr. Kandimalla received his M.Sc. in Biochemistry and Ph.D. in Chemistry from Andhra University, India, and carried out postdoctoral research at the Indian Institute of Science, and the University of Alberta prior to joining the Company. Dr. Kandimalla is a co-author of over 120 research publications and a co-inventor on 14 issued patents.

Dr. Ritter joined the Company in January 2006 as Intellectual Property Counsel. Prior to joining the Company, Dr. Ritter spent nine years assessing, patenting, licensing, and partnering a number of technologies created by academic institutions. From 1997 - 2005, Dr. Ritter served as the Associate Director of Technology Management at the University of Texas Health Science Center at Houston (UTHSC-H), and from 2005 - 2006 he was a Senior Licensing Associate with Massachusetts General Hospital. Dr. Ritter has extensive experience in contracting, as well as preparing, prosecuting, and managing patents in many fields. Dr. Ritter earned a B.S. in Nutritional Sciences from the University of Vermont in 1991, a Ph.D. in Nutritional Biochemistry from The Pennsylvania State University in 1995, completed a PhRMA Foundation post-doctoral fellowship in Molecular Pharmacology at UTHSC-H in 1997, and earned a J.D. from South Texas College of Law in 2004.

Dr. Sullivan joined the Company in 2002 as Senior Director, Preclinical Drug Development and subsequently rose to his current position, Vice President, Development Programs. His prior professional experience includes a variety of technical management roles with pharmaceutical companies, including Purdue Pharma and Adria, contract research organizations, including Oread, Battelle and Roma Toxicology Centre, and in veterinary medicine at International Minerals & Chemical. Dr. Sullivan brings broad expertise in the design, execution, and application of nonclinical drug development programs. His publications, presentations, and reports submitted to regulatory authorities have covered topics in preclinical models of efficacy, safety pharmacology, pharmacokinetics/ADME, carcinogenicity, mutagenicity, and reproductive toxicology as well as general toxicology/pathology. Dr. Sullivan earned his B.S. in Microbiology from Michigan State University. His graduate studies were at Purdue University, where he earned a M.S. degree in Health Physics and a Ph.D. in Toxicology.

Prior to joining the Company in 2005, Dr. Lough served for eight years in a variety of scientific and management positions with the genomics company Sequenom, Inc., including Manager of East Coast Operations. He previously served as a technology analyst with the translational drug development company Acretia, Inc., and as a principal scientist with the chemical genomics company NeoGenesis Pharmaceuticals, Inc (now Schering-Plough). Dr. Lough earned his B.Sc. (with honors) in Environmental Chemistry, his Ph.D. in Oligonucleotide Chemistry in 1996 from the University of Edinburgh, Scotland, and earned a Graduate Certificate in Intellectual Property from Northeastern University in 2004. Dr. Lough holds seven issued U.S. Patents in the field of nucleic acids technology.

Mr. Whalen joined the Company as a consultant in 1997 and was appointed Controller in 2001. Prior to joining the company, Mr. Whalen worked in a variety of financial accounting and reporting management positions at Bull HN Information Systems and Wyman-Gordon Company. He also worked in accounting, auditing and taxes at Deloitte & Touche (formerly Deloitte Haskins & Sells) Mr. Whalen became a Certified Public Accountant. Mr. Whalen earned a B.S. in Accounting at the University of Rhode Island in 1974 and an MBA from Babson College in 1985 where he concentrated in management and strategic planning. He also earned a Certificate in Biotechnology at Quinsigamond Community College.

Now retired, Mr. Reardon, who holds an MBA from Harvard Business School and is a certified public accountant (CPA), was Partner at PricewaterhouseCoopers (PWC) where he led the Life Science Industry Practice for New England and the Eastern United States. His responsibilities at PWC included supervising teams conducting client audits and serving as a Securities and Exchange Commission (SEC) Consulting Partner, which required him to work closely with SEC staff. Throughout his career, Mr. Reardon has been a highly visible member of the life sciences community, a frequent speaker at industry conferences, and an active member of the Biotechnology Industry Organization (BIO) and the Massachusetts Biotechnology Council (MBC). Mr. Reardon currently serves on the boards of directors at Idera Pharmaceuticals, Inc. and Synta Pharmaceuticals, Inc.

Mr. Hartley, age 66, has been President of Hartley Capital Advisors, a financial consulting firm, since June 2000. Mr. Hartley was Managing Partner of Forum Capital Markets LLC, an investment banking firm, from August 1995 to May 2000. Mr. Hartley also serves as a director of Universal Display Corporation, a developer of flat panel displays.

Mr. El Zein joined the Company’s Board in 1992 and was appointed Vice Chairman of the Board in 1997. He has been Director of Pillar Investment Ltd., a private investment and management firm, since 1991. In his capacity as a director of Pillar Investment, Mr. El Zein is also the general partner of Optima Life Sciences.